NKMax America Doses First Subject in Phase I Trial of SNK in Patients with Refractory Cancer

Stephen Chen, MBA, CTO of NKMax America commented, "Our ability to manufacture and deliver multiple doses of an NK cellular immunotherapy advances us towards our goal of providing a transformative cancer treatment to patients."